CA2638081A1 - Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions - Google Patents
Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions Download PDFInfo
- Publication number
- CA2638081A1 CA2638081A1 CA 2638081 CA2638081A CA2638081A1 CA 2638081 A1 CA2638081 A1 CA 2638081A1 CA 2638081 CA2638081 CA 2638081 CA 2638081 A CA2638081 A CA 2638081A CA 2638081 A1 CA2638081 A1 CA 2638081A1
- Authority
- CA
- Canada
- Prior art keywords
- ion source
- pyrophosphate
- ferric
- citrate
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositio ns are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventiona l soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.
Claims (23)
1. A water-soluble solid ferric pyrophosphate citrate chelate composition comprising:
iron citrate pyrophosphate; and phosphate in an amount of 2% or less by weight.
iron citrate pyrophosphate; and phosphate in an amount of 2% or less by weight.
2. The composition of claim 1, wherein iron is present in an amount of 7% to 11% by weight, citrate is present in an amount of from 14% to 30% by weight, and pyrophosphate is present in an amount of from 10% to 20% by weight.
3. The composition of claim 1, which is soluble in water in an amount of at least 1 gram per milliliter of water.
4. The composition of claim 1, wherein phosphate is present in an amount of 1.5% or less by weight.
5. The composition of claim 1, wherein phosphate is present in an amount of 1%
or less by weight.
or less by weight.
6. The composition of claim 1, wherein phosphate is present in an amount of 0.1% or less by weight.
7. A process for preparing a water-soluble solid ferric pyrophosphate citrate chelate composition comprising:
combining a citrate ion source, a pyrophosphate ion source, and a ferric ion source in water to form a solution;
adding an organic solvent in a volume sufficient to precipitate a solid ferric pyrophosphate citrate chelate composition from the resulting solution; and isolating the solid ferric pyrophosphate citrate chelate composition, said chelate composition having 2% or less phosphate by weight.
combining a citrate ion source, a pyrophosphate ion source, and a ferric ion source in water to form a solution;
adding an organic solvent in a volume sufficient to precipitate a solid ferric pyrophosphate citrate chelate composition from the resulting solution; and isolating the solid ferric pyrophosphate citrate chelate composition, said chelate composition having 2% or less phosphate by weight.
8. The process of claim 7, wherein the solid ferric pyrophosphate chelate composition has iron present in an amount of 7% to 11% by weight, citrate is present in an amount of from 14% to 30% by weight, and pyrophosphate is present in an amount of from 10% to 20% by weight.
9. The process of claim 7, wherein the amount of citrate ion source, pyrophosphate ion source, and ferric ion source are selected so that the molar ratio of ferric ion: citrate ion: pyrophosphate ion is 0.9 to 1.1 : 0.9 to 1:1 : 0.45 to 0.55.
10. The process of claim 7, wherein the amount of citrate ion source, pyrophosphate ion source, and ferric ion source each contain less than 250 micrograms of the metals aluminum, antimony, arsenic, bismuth, cadmium, copper, lead, mercury, molybdenum, thallium, and tin per gram of the ion source.
11. The process of claim 7, wherein the pyrophosphate ion source contains less than 0.1% phosphate.
12. The process of claim 7, wherein the pyrophosphate ion source contains less than 0.01% phosphate.
13. The process of claim 7, wherein the amount of said water used to dissolve the citrate ion source, the pyrophosphate ion source and the ferric ion source is from 1.5 milliliters to 10 milliliters for each gram of ferric ion source.
14. The process of claim 7, wherein said solution is heated to a temperature of from 70°C. to 85°C. before the ferric ion source is added and maintained at a temperature of from 70°C to 85°C after the ferric ion source is added and until complete dissolution of the ferric ion source has occurred.
15. The process of claim 14, wherein after the ferric ion source has completely dissolved, the temperature of the solution is lowered to a range of from 15°C. to 75°C. to prevent hydrolysis of pyrophosphate.
16. The process of claim 7, wherein the organic solvent is selected from methanol, ethanol, propanol, 2-propanol, acetonitrile, acetone, 2-butanone, and combinations of these solvents.
17. The process of claim 7, wherein the organic solvent is added to the solution containing the dissolved ferric ion source, the dissolved citrate ion source and the dissolved pyrophosphate ion source in an amount of from 10 to 25 milliliters per gram of the ferric ion source.
18. The process of claim 7, wherein the solid ferric pyrophosphate citrate chelate is dried at a temperature of 80°C. or less.
19. The process of claim 7, wherein the ferric ion source is selected from ferric sulfate, ferric sulfate hydrate, ferric chloride, ferric ammonium sulfate, and combinations of these materials;
the citrate ion source is selected from citric acid, monosodium citrate, disodium citrate, trisodium citrate, and combinations of these materials; and the pyrophosphate ion source is selected from disodium dihydrogen pyrophosphate, tetrasodium pyrophosphate, and a combination of both of these materials.
the citrate ion source is selected from citric acid, monosodium citrate, disodium citrate, trisodium citrate, and combinations of these materials; and the pyrophosphate ion source is selected from disodium dihydrogen pyrophosphate, tetrasodium pyrophosphate, and a combination of both of these materials.
20. A pharmaceutical composition comprising:
an oral or parenteral dosage form containing a therapeutically effective amount of a solid ferric pyrophosphate citrate chelate composition having 2% or less phosphate by weight.
an oral or parenteral dosage form containing a therapeutically effective amount of a solid ferric pyrophosphate citrate chelate composition having 2% or less phosphate by weight.
21. The composition of claim 20, which is a dialysate.
22. A process for treating iron deficiency comprising:
administering to a subject in need of treatment for iron deficiency, a pharmaceutical composition comprising an oral or parenteral dosage from containing a therapeutically effective amount of a solid ferric pyrophosphate citrate chelate composition having 2% or less phosphate by weight.
administering to a subject in need of treatment for iron deficiency, a pharmaceutical composition comprising an oral or parenteral dosage from containing a therapeutically effective amount of a solid ferric pyrophosphate citrate chelate composition having 2% or less phosphate by weight.
23. The process of claim 22, in which administration is via dialysis.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96132707P | 2007-07-20 | 2007-07-20 | |
US60/961,327 | 2007-07-20 | ||
US12/138,018 | 2008-06-12 | ||
US12/138,018 US7816404B2 (en) | 2007-07-20 | 2008-06-12 | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2638081A1 true CA2638081A1 (en) | 2009-01-20 |
CA2638081C CA2638081C (en) | 2012-07-10 |
Family
ID=40265353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2638081A Active CA2638081C (en) | 2007-07-20 | 2008-07-17 | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2638081C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016037836A1 (en) * | 2014-09-08 | 2016-03-17 | Unilever N.V. | Iron-fortified edible oil-and-water emulsion |
-
2008
- 2008-07-17 CA CA2638081A patent/CA2638081C/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016037836A1 (en) * | 2014-09-08 | 2016-03-17 | Unilever N.V. | Iron-fortified edible oil-and-water emulsion |
Also Published As
Publication number | Publication date |
---|---|
CA2638081C (en) | 2012-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120416T1 (en) | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions | |
AU621470B2 (en) | Stabilized nitric oxide-primary amine complexes useful as cardiovascular agents | |
JP2019194212A5 (en) | ||
JP2013519632A5 (en) | ||
JP2020514311A5 (en) | ||
JPH0356418A (en) | Aqueous solution of pholynate stable at temperature in refrigerator and preparation thereof | |
JP2013536195A5 (en) | ||
Chohan et al. | Transition metal acetylsalicylates and their anti-inflammatory activity | |
US20140088064A1 (en) | Process | |
Amtmann et al. | Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum | |
WO2013102806A1 (en) | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment | |
JP5325779B2 (en) | Pharmaceutical composition | |
JP2013504590A5 (en) | ||
CA2638081A1 (en) | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions | |
DK175775B1 (en) | ||
WO1995025513A1 (en) | Zinc compound and cyclodextrine for treatment of gastric disorders | |
EP3236949B1 (en) | Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof | |
CA2912128A1 (en) | Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer | |
US20150174245A1 (en) | Transparent gel | |
JP2019505571A5 (en) | ||
IT8922199A1 (en) | COMPLEX WITH CYCLODEXTRINS INDICATED FOR THE TREATMENT OF ALL ANEMIC FORMS OF FOLATE DEFICIENCY, THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS | |
JPH0513931B2 (en) | ||
CN108047090B (en) | Aniline hydroxamic acid urease inhibitor and preparation method and application thereof | |
CZ300120B6 (en) | Pharmaceutical composition intended for administration by injection | |
JP6760923B2 (en) | Composition containing apomorphine and divalent metal cations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |